How much platinum-based chemotherapy is enough in NSCLC?

被引：0
|
作者：
Solange Peters
Alex A. Adjei
机构：
[1] Centre Hospitalier Universitaire Vaudois (CHUV),Oncology Department
[2] Roswell Park Cancer Institute,undefined
来源：
Nature Reviews Clinical Oncology | 2015年 / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
With no large randomized phase III trials to provide definitive answers, the ideal number of platinum-based chemotherapy cycles in patients with advanced non-small-cell lung cancer has long been unclear. Most guidelines recommend a maximum of 4–6 cycles. Rossi and colleagues now suggest that four chemotherapy cycles is the optimal regimen.
引用
收藏
页码：8 / 10
页数：2
相关论文
共 50 条
  • [1] LUNG CANCER How much platinum-based chemotherapy is enough in NSCLC?
    Peters, Solange
    Adjei, Alex A.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (01) : 8 - 9
  • [2] Pharmacogenomics of platinum-based chemotherapy in NSCLC
    Hildebrandt, Michelle A. T.
    Gu, Jian
    Wu, Xifeng
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (07) : 745 - 755
  • [3] How much Platinum-Based Chemotherapy is Enough in Limited-Stage SCLC: A Propensity Score-Matched Analysis of a Prospective Trial
    Peng, F.
    Bao, Y.
    Hu, X.
    Chen, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S514 - S515
  • [4] Adjuvant chemotherapy: how much is enough?
    O'Regan, Ruth M.
    LANCET ONCOLOGY, 2009, 10 (12): : 1132 - 1133
  • [5] Sintilimab plus platinum-based chemotherapy for non-squamous NSCLC
    Venkatesan, Priya
    LANCET RESPIRATORY MEDICINE, 2020, 8 (10): : E76 - E76
  • [6] Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine
    Yin, Ji-Ye
    Li, Xi
    Zhou, Hong-Hao
    Liu, Zhao-Qian
    PHARMACOGENOMICS, 2016, 17 (12) : 1365 - 1378
  • [7] EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy
    Shah, Manan P.
    Aredo, Jacqueline, V
    Padda, Sukhmani K.
    Ramchandran, Kavitha J.
    Wakelee, Heather A.
    Das, Millie S.
    Neal, Joel W.
    CLINICAL LUNG CANCER, 2022, 23 (02) : E148 - E153
  • [8] Prognostic value of CTCs in advanced NSCLC patients treated with platinum-based chemotherapy
    Calabuig-Farinas, S.
    Muinelo-Romay, L.
    Abalo, A.
    Lago, R.
    Mosqueda, M.
    Rodriguez Lopez, C.
    Escorihuela, E.
    Gallach Garcia, S.
    Garcia, J.
    Blasco, A.
    Jantus-Lewintre, E.
    Lopez, R.
    Camps, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients
    Yin, Ji-Ye
    Li, Xi
    Li, Xiang-Ping
    Xiao, Ling
    Zheng, Wei
    Chen, Juan
    Mao, Chen-Xue
    Fang, Chao
    Cui, Jia-Jia
    Guo, Cheng-Xian
    Zhang, Wei
    Gao, Yang
    Zhang, Chun-Fang
    Chen, Zi-Hua
    Zhou, Hui
    Zhou, Hong-Hao
    Liu, Zhao-Qian
    CANCER LETTERS, 2016, 377 (01) : 65 - 73
  • [10] The Role of ADCY1 in Regulating the Sensitivity of Platinum-Based Chemotherapy in NSCLC
    Zou, Ting
    Liu, Jun-Yan
    Liu, Zhao-Qian
    Xiao, Di
    Chen, Juan
    PHARMACEUTICALS, 2024, 17 (09)
12345